GSK's Checkpoint Inhibitor and Chemotherapy Combo Improves Survival in Endometrial Cancer
GSK's checkpoint inhibitor, Jemperli, when added to chemotherapy, has been found to prolong the survival of patients with advanced or recurrent endometrial cancer in a Phase III study. The study met its primary overall survival endpoint, with patients receiving Jemperli-chemo treatment living longer than those in the comparator arm.